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Introduction: Infections caused by Streptococcus pneumoniae (pneumococcus) still represent a
challenge for health systems around the world.
Objective: The objective of this study was to assess microbiological and clinical aspects in
hospitalized patients with invasive pneumococcus disease between 1998 and 2013.
Materials and methods: This was a retrospective study that analyzed the results of pneumo-
coccus identiﬁcation, serotyping, and susceptibility testing found in the Adolfo Lutz Institute
databank. Personal variables, medical history and clinical outcome of patients admitted with
invasive pneumococcal disease were analyzed. These were obtained from records of a public
teaching hospital – Hospital das Clínicas Faculdade de Medicina Ribeirão Preto.
Results: The sample comprised 332 patients. Patient age ranged from less than one month to
89  years old (mean 20.3 years) and the sample was predominately male. Pneumonia (67.8%)
was the most common disease, accounting for 18.2% of deaths. Serotypes 14, 1, 3, 9V, 6B, 6A,
23F, 19A, 18C, 19F, 12F, and 4 were the most common (75.3%). Most patients, or 67.5%, were
cured without any complication (success), 6.9% had some type of sequela (failure), and 25.6%
died  (failure). In the case of deaths due to meningitis, strains of fully penicillin resistant
pneumococcus were isolated. Furthermore, 68.2% of patients who died presented some typeof  comorbidity. The 60 and older age group presented the most signiﬁcant association (OddsRatio  = 4.2), with outcome failure regardless of the presence of comorbidity. Serotype 18C was
the  most signiﬁcant risk factor both in raw analysis (Odds Ratio = 3.8) and when adjusted
for  comorbidity (Odds Ratio = 5.0) or age (Odds Ratio = 5.4). The same occurred with serotype
12F  (respectively, Odds Ratio = 5.1, Odds Ratio = 5.0, and Odds Ratio = 4.7)
 Part of a doctoral thesis “Serotypes and antimicrobial resistance proﬁle of Streptococcus pneumoniae:  clinical implications for invasive
disease and the national immunization program” (1998–2013).
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Conclusion: The present ﬁndings highlight the importance of IPD among young adults and
older adults. In the era of conjugate vaccines, monitoring serotypes in different age groups
is  essential to assess the impact and adequacy of immunization.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
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Antroduction
ven with the possibility of immunoprevention of several
erotypes, the World Health Organization has indicated and
stimated 1.6 million deaths per year due to pneumococcus
isease. The data demonstrate greater prevalence in develop-
ng countries and 0.7–1 million children less than ﬁve years of
ge.1 In countries with immunization for H. inﬂuenzae serotype
, pneumococcus has become the most common cause of
nvasive disease.2 Based on data from the Hospital Informa-
ion System (HIS), Novaes, Sartori, and Soárez3 found that
here were 34,217 hospitalizations due to pneumococcal dis-
ase in the Brazilian Uniﬁed Health System (SUS) between
006 and 2014. This ﬁgure represented 0.1% of the total of
dmissions, of which 64.8% were pneumococcal pneumonia.
 study on the clinical and epidemiological proﬁle of patients
ith pneumonia acquired in the community observed among
ndividuals under the age of 60 an elevated percentage of the
isease, in addition to worsened clinical outcomes. Lethality
as low (4.9%) and concentrated among the youth. In Brazil,
hese patients are usually hospitalized in order to ensure
ccess to medication and clinical follow-up, especially in the
ase of older adults and individuals with underlying chronic
iseases.4 According to the Brazilian Ministry of Health,5
etween 2000 and 2008 pneumococcal meningitis represented
1% of bacterial meningitis recorded in the Notiﬁable Diseases
nformation System (SINAN), with an average of 1218 cases
er year and 30% lethality. In order to minimize the impact of
neumococcal disease, in 2009 the National Agency of Health
urveillance (ANIVSA) approved the use of conjugate pneumo-
occal polysaccharide vaccine (PVC) with 10 speciﬁc serotypes
PVC10) in children under the age of two. Thus, Brazil was one
f the ﬁrst countries to include the VPC10 in the immunization
chedule of the National Immunization Program (PNI).6,7 The
bjective of this study was to analyze clinical and microbiolog-
cal aspects of people hospitalized with IPD between 1998 and
013, and therefore evaluate the outcome of cases in relation
o the serogroups.
aterials  and  methods
his was a retrospective cross-sectional study that analyzed
ecords from 1998 to 2013. These records contained the results
f 332 isolated pneumococcal strains in patients with invasive
neumococcus disease (IPD) hospitalized in the Ribeirão Preto
chool of Medicine Teaching Hospital–University of São Paulo
HCRP-USP), Brazil. The pneumococcus samples included in
his study were isolated in the HCRP laboratory and sent to
dolfo Lutz Institute in Ribeirão Preto (IAL-RP) in order tolicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
conﬁrm the species, and then forwarded to the National Lab-
oratory of Public Health (Adolfo Lutz Institute in São Paulo)
for serotyping and to determine the antimicrobial susceptibil-
ity proﬁle. Toward this end, microbiological information was
obtained from the IAL-RP archives and the clinical aspects of
patients retrieved from the surveillance system of HCRP-USP
epidemiological center.
Analysis  and  inference  of  results
The information gathered was saved on an MS  Excel XP
spreadsheet and then exported to SPSS (Statistical Package
for the Social Sciences), version 19.0 for statistical analyses:
descriptive analysis through absolute and relative frequen-
cies and then means, standard deviations, medians, and
minimum and maximum values were calculated. Possible
associations between outcomes: success (cure with no com-
plications) or failure (cure with complications or death).
The studied variables (gender, age, presence of comorbidity,
and the most common serotypes) were analyzed using chi-
square test and univariate (raw OR) and multiple (adjusted
OR) logistic regression. Level of signiﬁcance was set at
p ≤ 0.05. This was a retrospective study, with limitations asso-
ciated with the nature of information in quantitative and
qualitative terms. The present study was approved by the
human subject research ethics committee, protocol CAAE:
26759714.80000.5393.
Results
Among the 332 patients with IPD, age ranged from less than a
month to 89 years old, with mean age of 20.3 (standard devi-
ation = 25.5 years, median 4 years), with a predominance of
male patients (61.1%). The most common clinical diagnoses
were pneumonia (67.8%), followed by meningitis and bac-
teremia (22.9%). After 2010, there was a signiﬁcant reduction
in the number of pneumococcus cases sent for identiﬁcation
(Table 1). Forty-two different serotypes of S. pneumoniae were
identiﬁed, of which 75.3%, in decreasing order, were serotypes
14, 1, 3, 9V, 6A, 6B, 23F, 19A, 18C, 19F, 12F, and 4 with at least
10 isolates. Furthermore, there was a progressive increase
of serotypes 3 and 6A, which were present in the 13-valent
conjugate pneucomococcal vaccine, and serotypes 12F and
18C (non-vaccine). There was a reduction in serotypes 14, 1,
and 23F included in VPC10 (Table 2). The prevalence of the
serogroups varied according to age of the patients. Serogroup
14 was the most common in children younger than ﬁve years
of age, and serogroup 3 was the most common in the age
range greater than ﬁve years old (Table 3). In children younger
than ﬁve years of age, in the period prior to the VPC10, there
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Table 1 – Demographic characteristics and clinical
diagnosis of patients with IPD registered in the HCRP
Databank, 1998–2013.
Variable Category No. %
Gender Male 203 61.1
Female 126 38.0
Unknown 3 0.9
Age group (years) <1 52 15.7
1–2 59 17.8
2–5 57 17.2
Subtotal <5 168 50.7
5–20 40 12.0
20–60 83 25.0
≥60 39 11.7
Subtotal ≥5 162 48.7
Unknown 2 0.6
Period 1998–2002 81 24.4
2003–2010 205 61.7
2011–2013 46 13.9
Disease Pneumonia 225 67.8
Meningitis 76 22.9
Bacteremia/septicemia 26 7.8
Others 5 1.5
Total 332 100.0
IPD, invasive pneumococcal disease; HCRP, Ribeirão Preto Teaching
Table 2 – Serotypes of S. pneumoniae most often isolated
from IPD patients registered in the HCRP Databank,
1998–2013.
Serotypes Periods Total
1998–2002 2003–2010 2011–2013 No. %
No. %a No. %a No. %a
14 31 38.3 51  25.0 3 6.4 85 25.6
1 7 8.6 17 8.3 0 0.0 24 7.2
3 2 2.5 16 7.8 5 10.6 23 6.9
9V 5 6.2 9 4.4 2 4.3 16 4.8
6A 3 3.7 10 4.9 3 6.4 16 4.8
6B 3 3.7 10 4.9 2 4.3 15 4.5
23F 3 3.7 12 5.9 0 0.0 15 4.5
19A 6 7.4 5 2.5 1 2.1 12 3.6
18C 5 6.2 4 2.0 2 4.3 11 3.3
19F 0 0.0 10 4.9 1 2.1 11 3.3
12F 0 0.0 4 2.0 6 12.8 10 3.0
4 1 1.2 8 3.9 1 2.1 10 3.0
Others 15 18.5 48 23.5 21 44.7 84 25.3
4% in patients less than ﬁve years of age. Regarding the antibi-Hospital.
was a prevalence of serogroups 14 (46.4%), 1 (8.6%), 19A (6.6%),
6A (6.0%), and 9V (4.6%) in hospitalized patients. After 2010,
serogroups 6A (23.1%), 14 (23.1%) and 3 (23.1%) were the pre-
vailing serogroups in this age range. Treatment was successful
among 67.5% of patients, with no complications, while 32.5%
of cases resulted in treatment failure, with 25.6% deaths and
6.9% with some type of sequelae. Of the IPD cases that resulted
in death, 68.2% (58/85) occurred in patients older than ﬁve
years of age. Among patients less than ﬁve years old, 46%
(17/37) of the deaths were associated with meningitis and 9.8%
Table 3 – Serogroups of S. pneumoniae most commonly isolated
were assisted at the Regional Health Care Network 13, accordin
Serotypes Age range (ye
<1 1–2 2–5 Subtotal <5 
No. %a No. %a No. % No. %a No.
14 20 38.5 26 44.1 29 50.9 75 44.6 4 
1 1 1.9 2 3.4 10 17.5 13 7.7 8 
3 3 5.8 5 8.5 2 3.5 10 6.0 1 
9V 2 3.8 4 6.8 1 1.8 7 4.2 2 
6A 6 11.5 2 3.4 5 8.8 13 7.7 2 
6B 4 7.7 3 5.1 0 0.0 7 4.2 0 
23F 2 3.8 2 3.4 0 0.0 4 2.4 3 
19A 6 11.5 3 5.1 1 1.7 10 5.9 0 
18C 2 3.8 2 3.4 3 5.3 7 4.2 1 
19F 0 0.0 0 0.0 2 3.5 2 1.2 3 
12F 1 1.9 0 0.0 0 0.0 1 0.6 2 
4 0 0.0 0 0.0 0 0.0 0 0.0 2 
Others 5 9.6 10 16.9 4 7.0 19 11.3 12 
Total 52 100.0 59 100.0 57 100.0 168 100.0 40 
a Refers to the total of cases in each age range, except for two cases that wTotal 81 100.0 204 100.0 47 100.0 332 100.0
a Refers to the total number of IPD cases in each period.
(4/41) with pneumonia. Of the 85 deaths (25.6%) due to IPD,
meningitis was involved in 43.5% of the cases, with a 48.7%
lethality rate (37/76) across all age groups. Of all meningi-
tis related deaths, 29.7% (11/37) occurred in children younger
than one year, and 27.0% (10/37) in patients with ages between
20 and 59, representing a lethality rate of 21.2% (11/52) for
patients less than one year old, and 12.0% (10/83) among those
aged 20 through 59. Pneumonia accounted for 48.2% of deaths,
with a lethality rate of 18.2% (41/225). Of all deaths due to
pneumonia, 21.2% (18/85) occurred in the 20–59 age group, andotic susceptibility proﬁle of the strains, 9.4% (n = 8) of deaths
due to meningitis were caused by penicillin-resistant S. pneu-
moniae (penicillin MIC  ≥0.125 g/mL), represented by serotypes
 from patients with invasive pneumococcal disease who
g to the age of the patients, from 1998 to 2013.
ars) Total
5–20 20–60 ≥60 Subtotal ≥5 No. %
 %a No. %a No. %a No. %
10.0 6 7.2 0 0.0 10 6.2 85 25.8
20.0 2 2.4 1 2.6 11 6.8 24 7.3
2.5 6 7.2 6 15.4 13 8.0 23 7.0
5.0 4 4.8 3 7.7 9 5.5 16 4.8
5.0 1 1.2 0 0.0 3 1.8 16 4.8
0.0 5 6.0 3 7.7 8 4.9 15 4.5
7.5 6 7.2 2 5.1 11 6.8 15 4.5
0.0 1 1.2 1 2.6 2 1.2 12 3.6
2.5 1 1.2 2 5.1 4 2.5 11 3.3
7.5 4 4.8 2 5.1 9 5.5 11 3.3
5.0 6 7.2 1 2.6 9 5.5 10 3.0
5.0 6 7.2 2 5.1 10 6.2 10 3.0
30.0 35 42.2 16 41.0 64 39.5 83 25.1
100.0 83 100.0 39 100.0 162 100.0 330 100.0
ere excluded due to lack of information.
b r a z j i n f e c t d i s . 2 0 1 6;2 0(3):242–249 245
Table 4 – Demographic characteristics and presence of comorbidity among IPD patients registered in the HCRP Databank
by case outcome, 1998–2013.
Variable Category Cure no sequela Cure with sequela/death Total p-value
No. %a No. %a No. %
Gender Male 134 66.0 69  34.0 203 61.1 0.568
Female 87 69.0 39 31.0 126 38.0
Unknown 3 0.9 0 0.0 3 0.9
Age (years) <1 38 73.1 14 26.9 52 15.7 <0.001
1–2 44 74.6 15 25.4 59 17.8
2–5 48 84.2 9 15.8 57 17.2
Subtotal <5 130 77.4 38 22.6 168 50.6
5–20 35 87.5 5 12.5 40 12.0
20–60 44 53.0 39 47.0 83 25.0
≥60 15 38.5 24 61.5 39 11.7
Subtotal ≥5 94 58.0 68 42.0 162 48.7
Unknown 1 0.3 1 0.3 2 0.6
Comorbidity No 108 77.1 32 22.9 140 42.2 0.002
Yes 112 61.2 71 38.8 183 55.1
Unknown 4 44.4 5 55.6 9 2.7
Total 332 100.0
a Refers to the total of each category.
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4 (3.5%, n = 3), 23F (2.4%, n = 2), 19A (1.2%, n = 1), 6B (1.2%, n = 1),
nd 9V (1.2%, n = 1). A total of 68.2% of patients presented
omorbidities, the most common being HIV/AIDS (27.6%),
lcoholism, and cancer (17.2%). Serotypes 12F, 14, 18C, 9V, 18A,
9A, and 23F accounted for 65% of all deaths due to meningi-
is, while serotypes 3, 14, 9V, 6B, 23F, and 19F were involved
n 63.4% of deaths due to pneumonia. There was no associa-
ion between patient gender and outcome in terms of success
r failure (p = 0.568). Regarding the presence of complications
nd death related to patient age, we found that the older
he patient, the higher the percentage of sequelae and death
p < 0.001). Furthermore, the presence of comorbidity was asso-
iated with outcome failure (p = 0.002). Among patients with
o comorbidities, 22.9% presented treatment failure, whereas
mong those with comorbidities the failure rate was 38.8%
Table 4). Our analysis of each serotype with at least 10 iso-
ates in relation to clinical outcomes revealed no signiﬁcant
ifference for serotypes 3, 9V, 6B, 6A, 23F, 19F, 19A, and 4.
erotype 18C had the highest failure rate when compared with
on-18C serotypes (63.6 × 31.5%; p = 0.025). The same was true
or serotype 12F (70.0 × 31.4%; p = 0.010). Serotype 14 presented
he lowest failure rate when compared to all other serotypes
17.1 × 37.6%; p = 0.001), as well as serotype 1 (8.0 × 34.5%;
 = 0.006). Univariate analysis demonstrated that patients less
han 20 years were at the greatest risk. After adjusting for the
resence of comorbidities, age or serotype were signiﬁcantly
ssociated with type of outcome only in those with 60 years or
ore (OR = 4.2) (Table 4). Furthermore, serotypes 14 (p = 0.001)
nd 1 (p = 0.006) were less likely to result in failure (OR = 0.3 and
R = 0.2, respectively), regardless of the presence of comor-
idities (OR = 0.4 and OR = 0.2, respectively) (Table 5). However,
fter adjusting for age, this association was no longer signif-
cant (Table 4). In the present study, serotypes 18C (p = 0.025)
nd 12F (p = 0.010) resulted in the greatest failure rates when
ompared to the other serotypes. The presence of 18C repre-
ented a signﬁicant risk factor, both in unadjusted analysisital.
(OR = 3.8) and after adjusting for comorbidity (OR = 5.0) or age
(OR = 5.4), as did serotype 12F (OR = 5.1, OR = 5.0, and OR = 4.7,
respectively) (Table 6).
Discussion
There is a vast amount of literature with information on the
characteristics of Streptococcus pneumoniae strains that cause
invasive disease, especially related to the development of new
vaccines. In countries in which the conjugate pneumococcal
vaccine was included in the immunization schedule, there
was a sharp decline in hospitalization rates due to pneumo-
nia, especially among children under the age of three years.8
In developing countries, approximately 15 million children
with pneumonia were hospitalized every year9; this IPD stands
out due to its high lethality.10 The reduction in pneumococ-
cus samples sent for identiﬁcation after 2010 was compatible
with the ﬁndings of Afonso and collaborators,7 who  found
that one year after the implementation of VPC10 in Brazil
there was a drop in the number of hospitalized children with
pneumonia in the municipalities of Belo Horizonte, Recife,
and Curitiba. In Brazil, data from the public health informa-
tion system (DATASUS) indicate pneumonia as the leading
cause of hospital admissions, with the greatest occurrence at
extremes of age, affecting approximately 2.1 million Brazilians
per year.11 Considering all age groups, the incidence density
of pneumococcal meningitis in the state of São Paulo during
the period of this study ranged between 0.9 and 1.5/100,000
inhabitants.12 It was observed that 68.2% of deaths among
all of the analyzed IPDs occurred in patients under the age
of ﬁve. The global lethality rate of IPDs in industrialized
countries ranges from 15% to 20% among adults, and from
30% to 40% among patients with comorbidities, or older adults
whose immunological function is compromised.13 In Euro-
pean countries, Navarro-Torné et al.14 reported a 15.9% death
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Table 5 – Most common serotypes of S. pneumoniae in comparison to other serotypes isolated from IPD patients
registered in the HCRP Databank by case outcome, 1998–2013.
Serotypes Cure no sequela Cure with sequela/death Total p-value
No. %a No. %a No. %
14 68 82.9 14 17.1 82 100.0 0.001
Non-14 156 62.4 94 37.6 250 100.0
1 23 92.0 2 8.0 25 100.0 0.006
Non-1 201 65.5 106 34.5 307 100.0
3 14 58.3 10 41.7 24 100.0 0.321
Non-3 210 68.2 98 31.8 308 100.0
9V 9 52.9 8 47.1 17 100.0 0.189
Non-9V 215 68.3 100 31.7 315 100.0
6B 9 56.2 7 43.8 16 100.0 0.326
Non-6B 215 68.0 101 32.0 316 100.0
6A 12 80.0 3 20.0 15 100.0 0.289
Non-6A 212 66.9 105 33.1 317 100.0
23F 11 73.3 4 26.7 15 100.0 0.620
Non-23F 213 67.2 104 32.8 317 100.0
19F 5 45.5 6 54.5 11 100.0 0.113
Non-19F 219 68.2 102 31.8 321 100.0
19A 9 64.3 5 35.7 14 100.0 0.795
Non-19A 215 67.6 103 32.4 318 100.0
18C 4 36.4 7 63.6 11 100.0 0.025
Non-18C 220 68.5 101 31.5 321 100.0
12F 3 30.0 7 70.0 10 100.0 0.010
Non-12F 221 68.6 101 31.4 322 100.0
4 7 70.0 3 30.0 10 100.0 0.862
Non-4 217 67.4 105 32.6 322 100.0
 Hospa Refers to the total of each assessed serotype.
IPD, invasive pneumococcal disease; HCRP, Ribeirão Preto Teaching
rate due to pneumococcal meningitis, with an association
between penicillin-resistant of S. pneumoniae and increased
risk of death. In the present study, we  observed a 43.5% rate of
meningitis, with 9.4% of deaths involving penicillin-resistant
strains of S. pneumoniae. In the city of Salvador15 and in the
Amazon state,16 the death rate due to pneumococcal menin-
gitis surpassed 37.0% and 32.4%, respectively, in all age groups.
Based on SINAN data from 2001 to 2010, Grando et al.17 found
Table 6 – Adjusted analysis of factors associated with outcome
Databank, 1998–2013.
Variable Category Raw OR 
Age
(years)
<1  1 
1–2 0.9 [0.4; 2.2] 
2–5 0.5 [0.2; 1.3] 
5–20 0.4 [0.2; 1.2] 
20–60 2.4 [1.1; 5.1] 
≥60 4.3 [1.8; 10.6] 
Serotype
18C Yes 3.8 [1.1; 13.3] 
No 1.0 
12F Yes 5.1 [1.3; 20.1] 
No 1.0 
14 Yes 0.3 [0.2; 0.6] 
No 1.0 
1 Yes 0.2 [0.1; 0.7] 
No 1.0 
IPD, invasive pneumococcal disease; HCRP, Ribeirão Preto Teaching Hospitital.
that the annual mean death rate due to pneumococcal menin-
gitis in Brazil was 33.6% and 31.3% in children less than ﬁve
years old and less than one year old, respectively. In addition
to presenting high mortality rates, meningitis is also a seri-
ous concern due to the association with severe neurological
complications, as well as high treatment costs. Edmond and
collaborators,18 attributed serious sequelae to pneumococ-
cal meningitis, such as hydrocephalus, cognitive and motor
 failure among patients with IPD registered in the HCRP
OR adjusted for comorbidity OR adjusted for age
1
0.9 [0.4; 2.2]
0.5 [0.2; 1.4]
0.4 [0.1; 1.2]
2.1 [0.9; 4.8]
4.2 [1.6; 10.9]
5.0 [1.4; 18.0] 5.4 [1.4; 20.9]
1.0 1.0
5.0 [1.2; 20.1] 4.7 [1.1; 21.3]
1.0 1.0
0.4 [0.2; 0.8] 0.5 [0.3; 1.1]
1.0 1.0
0.2 [0.1; 0.9] 0.3 [0.1; 1.2]
1.0 1.0
al.
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eﬁcits, hearing loss, behavioral problems, and learning dis-
rders. In the present investigation, the rate of sequelae was
.9%. Kyaw et al.19 indicated that, in the United States, pneu-
ococcal disease in adults was associated with a higher
ncidence among patients with HIV/AIDS, alcoholism, heart
isease, respiratory diseases, and diabetes mellitus. In accor-
ance with the results obtained in the present study, 68.2%
f patients who  died presented some type of comorbidity,
rimarily HIV/AIDS. In Brazil, data on lethality of respira-
ory diseases are scarce. However, according to Cashat-Cruz
t al.,20 death from acute respiratory diseases is among the
ost common causes of death in the Americas, account-
ng for approximately 40% of cases. This study demonstrated
hat pneumonia-related mortality was high (48.2%), especially
mong adults, and only 4% of cases involved patients younger
han ﬁve. In Spain, mortality related to pneumococcal pneu-
onia varied from 7.4% to 13% dependending on the patient’s
ge.21 In Portugal, pneumonia is the second leading cause
f death among patients hospitalized with respiratory dis-
ases, with a 22% lethality rate.22 In the present study IPD
ases were more  often caused by serotypes 18C and 12F, rep-
esenting a signiﬁcant risk factor for failure. Several authors
uggest that the different serotypes possess have different
otential to cause invasive disease, indicating an association
etween fatal outcomes for pneumococcal disease and capsu-
ar serotypes of pneumococcus.14,23–27 However, there was a
ariation in serotypes more  frequently involved in fatal cases,
amely serotypes 3, 6B, 9N, 19F, and 7F described by these
uthors as the most invasive and involved in unfavorable out-
omes; on the other hand serotype 1 presented the lowest risk
f death. Furthermore, these authors also found serotypes 3,
B, 18C, and 19F to be among the most frequently involved in
atient deaths. In turn, serotypes 1, 7F, 8, 6A, and 15 showed
o relation with fatal cases. In this context, information about
he risk associated with different serotypes, in terms of differ-
nt outcomes of IPDs, allows us to estimate the expectation
efore new vaccine formulas; for example the inclusion of
erotype 3 may not help reducing the morbidity associated
ith IPD.24 However, the results of this study underscore the
nﬂuence of age as a risk factor for acquiring IPD, corroborating
he ﬁndings of Navarro-Torné,14 who indicated that individ-
als older than 65 had a higher tendency to develop serious
neumococcal diseases associated with a greater rate of mor-
idity and mortality than children less than ﬁve years old. As
bserved in the present study, the higher risk related to older
dults is not dependent on the presence of comorbidities, as
as found in a study by Santos et al.,28 who demonstrated
hat the presence of comorbidities did not seem to inﬂuence
he ﬁnal outcome of IPDs. Due to impaired splenic function,
mmunosenescence, and changes in the respiratory tract,29
lder adults are more  susceptible to pneumococcal disease.
n Brazil, the Geriatric Vaccination Guideline30 recommends
he 23-valent pneumococcal polysaccharide vaccine (PPV23)
nd the 13-valent pneumococcal conjugate vaccine (PVC13)
or patients above the age of 60 or those who have speciﬁc
hronic underlying diseases. However, the 13-valent vaccine is
ot available for older adults through the national immuniza-
ion program, and is offered only by private vaccination clinics.
n turn, the PPV23 is administered to institutionalized older
dults and, when medically indicated, to those who are part of6;2 0(3):242–249 247
the high-risk group for pneumococcal infection. In this sense,
after assessing the cost of PPV23 in adults aged 60 or older,
Tonolio Neto and colleagues31 found that, in Brazil, incor-
porating this vaccine to the national immunization program
would be very cost-effective given the costs of hospitalization
and absenteeism. However, despite the evidence pointing to
the effectiveness of the VPP23 against IPDs,32 its effectiveness
in preventing pneumonia in adults and high-risk patients,
for whom it is recommended,33 as well as its preventive
action in immunosuppressed patients, is still questioned.34 In
this context, a study conducted in Germany concluded that
in comparison with the VPP23, the VPC13 was better indi-
cated to reduce the burden of pneumococcal disease, even
economically.35 Another study conduced by Polish researchers
found that older adults above the age of 65, regardless of risk
for contracting pneumococcal infection, should be vaccinated
with VPC13.36 In 2010, based on the data about pneumococ-
cal pneumonia in Spain, Luja et al.37 suggested that the new
VPC13 would result in a sharp decline in mortality among the
older adult population. Ardanuy and collaborators38 empha-
sized the importance of administering the conjugate vaccine
to adults, suggesting that the VPC13 should be used in Spain
for that age group. Corroborating the data of a double-blind
randomized trial conducted in Holland, which found a reduc-
tion in pneumococcal pneumonia among older adults after
immunization with VPC13,39 Picazo et al.40 found that VPC13
does not lead to the phenomenon of serotype replacement as
observed with the 7-valent pneumococcal vaccine. In light of
the above and the high incidence and mortality rate of IPDs
among adults and especially older adults, we  emphasize the
need to review vaccination recommendations and programs
for these age groups, especially considering the increase in
serotypes 3 and 6A observed in the present study. However,
there is controversy surrounding the effectiveness of these
vaccines in adults, as well as the most appropriate choice
for this population.41 In this context, O’Brien42 highlighted
the importance of immunogenicity studies to determine the
effectiveness of conjugate vaccines against pneumonia in
adults, especially in the context of co-infection with the H1N1
inﬂuenza virus.
Conclusion
The pneumococcus isolates among patients hospitalized with
invasive pneumococcal disease presented variability in terms
of circulating serotypes. This emphasizes the importance of
ongoing monitoring of invasive strains in different manifes-
tations of pneumococcal disease, especially considering the
progressive increase in serotypes 3 and 6A present in the
13-valent conjugate pneumococcal vaccine, and serotypes
12F and 18C, which are non-vaccine serotypes. Serotypes
18C and 12F were signiﬁcant risk factors both in unadjusted
and adjusted analysis for comorbidity and age. Furthermore,
regarding case outcomes, 25.6% resulted in death, especially
among patients with meningitis. Patients aged 60 years or
older presented the most statistically signiﬁcant association
(OR = 4.2) with outcome failure, regardless of the presence
of comorbidities. In light of this information we recognize
the importance of conducting surveillance studies that can
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underpin the process of reviewing and making decisions
regarding public policies and immunization programs for all
adults and for older adults in particular. In addition, in the
age of conjugate vaccines, information about the distribution
of serotypes among different age groups is essential to assess
the impact and adequacy of immunization programs.
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